Molecule to Market: Inside the outsourcing space

Diversity in life sciences

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Raman Sehgal for a special lookback episode on the topic of diversity in the life sciences space.

This week’s episode features excerpts from conversations with;

• Barbara Morgan (Lubrizol at time of recording), now Global Vice President, Pharma and Biotechnology at Kerry discussing; gender diversity and the network of women supporting each other in their roles.
• Tia Lyles-Williams, founder & CEO at LucasPye Bio discussing; the recent political climate and how that has affected steps forward in diversity and inclusion.
• Jeff Dill, CEO at Vynamic discussing; the importance of diversity at his organization, and what they have put in place to ensure EDI goals are being achieved.
• Andrew Moore, General Manager at Pfizer Center One discussing; his experience as a person of color in the sector, and how the conversation has changed in his time.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The CDMO CEO on the frontline of a Covid mission

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Tom Ross, President and CEO at Grand River Aseptic Manufacturing (GRAM).

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Tom, covering:

• How a passive investment in a small growing business led to running one of the most reputable CDMOs in the US
• Insights of how to pivot from lumpy clinical supply to sustainable commercial revenues
• The ups and downs, opportunities and challenges of growing a business at over 700pc+ as one of Inc Magazine’s fastest growing companies in the US
• Being on the inside of Operation Warp Speed (OWS) and what it took to gear up for global Covid vaccine supply
• Dealing with the Covid comedown and transitioning a 100% capacity utilization with new projects including the monkeypox vaccine

During his career, Tom has held senior executive roles at a large, publicly held pharmaceutical company and at leading, smaller entrepreneurial organizations. He spent eight years at Perrigo Company, a multi-billion-dollar generic and OTC pharmaceutical company, where he served on the executive committee and led the financial team. Tom left Perrigo to help set up the processes, systems and infrastructure for two smaller, high-growth companies. He also served as managing director at DWH, LLC, a consulting company focused on helping emerging businesses maximize value.

Tom, who joined GRAM in 2013, received his Bachelors in Accounting from Michigan State University and completed coursework for an MBA at the University of Miami. As President and Chief Executive Officer at GRAM, Tom Ross uses his extensive managerial and technical expertise to create a culture where employees can maximize their performance. A skilled communicator, Tom helps develop teams to create compliant processes and systems that deliver results to clients.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Industry insights you cannot afford to miss

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Ian Tzeng, Managing Director at L.E.K. Consulting.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ian, covering:

• Insights, trends and advice for CROs, CDMOs and pharma services firms from one of the most prominent life science consultants.
• What he gained from his time studying at Harvard and the importance of genuine curiosity and a multi-disciplinary way of thinking.
• The complexity of modality and technology fragmentation, and the challenge of picking the right ones from a CDMO perspective.
• Why focusing on ‘conserved areas’ and ‘platform technologies’ could be a smart move when thinking about diversification and long term investments.
• The shift we are seeing from volume-based blockbuster drugs that deliver billions of pills to the masses, to targeted speciality drugs, to even more advanced therapies for micro-patient populations.

Based in the Boston, Ian has 20+ years of consulting experience in growth strategy, regulated markets, innovation, pricing, and mergers and acquisitions. He directs projects across the healthcare spectrum with particular emphasis on Biopharmaceuticals & Life Sciences and MedTech practices.

As a focus area, he leads L.E.K.’s pharmaceutical contract services practice. Additionally, Ian has extensive consulting and board experience with non-profit organizations in education, arts, LGBTQ+ advocacy, and public service. He received a Bachelor of Arts degree, magna cum laude, in Chemistry from Harvard College and is a George F. Baker Scholar, Master of Business Administration with high distinction from Harvard Business School.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

 

The Puzzle-Solving Lifelong Science Geek

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Claire, covering:

• How a family ritual of solving puzzles played a role in developing an entrepreneurial spirit of problem solving
• Learn about how and why Northern Texas is becoming a destination for biotech and life sciences
• Going viral for being viral... and why covid was the time for immunologists to shine
• The opportunities and challenges of introducing innovative, disruptive technology into the biopharma space

Claire Aldridge, Ph.D. is Chief Strategy Officer for Form Bio, the first spinout from the de-extinction and biodiversity company, Colossal Biosciences. Prior to this role, she was Senior Vice President, Chief of Staff and Corporate Strategy at Taysha Gene Therapies, a Dallas based company focusing on eradicating monogenic CNS disease. She previously served as Associate Vice President for Commercialization and Business Development at UT Southwestern Medical Center and VP, Venture Development with Remeditex Ventures, a local biotech venture fund.

Dr. Aldridge brings more than 20 years’ experience facilitating the translation of scientific discoveries into patient and commercial benefits. Dr. Aldridge is also on the Scientific Advisory Board for Colossal Biosciences, the Board of Directors for MedCognetics and 4E Therapeutics and is the chair for the Industry Advisory Council for the UT Dallas Department of Biomedical Engineering. Dr. Aldridge received her Ph.D. from Duke University in the Department of Immunology and Program in Genetics, and her Bachelor of Science in Biomedical Science is from Texas A&M University.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

The CDMO with a capital D

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Harry Christiaens, CEO at Ardena.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Harry, covering:

• How a regulatory change led a small consultancy down the path of becoming one of Europe’s most respected mid-sized CDMOs
• The easy-theory of an M&A buy-and-build strategy, versus the challenging practical realities after acquiring and integrating five businesses
• Key considerations and questions you should ask before selecting a private equity partner
• The role of nano-technology in producing nanomedicines for effective targeting of disease…but also the challenges of dealing with this enabling platform
• Why there is cause for optimization for CDMOs when looking at the robust R&D funding environment and forecasted outsourcing growth

Harry has significant leadership experience with 20+ years in the pharma and biotech industry. He successfully transformed Pharmavize, a regulatory consultancy company into a leading CDMO, establishing a GMP team and infrastructure from scratch. Since 2015, he led the acquisitions and integration of five companies providing highly complementary services. He successfully integrated the service offering of the acquired companies onto one platform, creating the Ardena brand.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

100 episodes of Molecule to Market: looking back, lessons & laying the land for 101

In this special episode of Molecule to Market, we are marking our 100th episode! Join us as we look back, review our learnings and lay the land for episode 101…

For those that have been here since the beginning, we are incredibly grateful for your constant support and feedback. To our new listeners, thank you for joining the journey, seeing us through to 30,000 downloads and beyond. 

To our guests - thank you for being a part of this experience with us and taking the time to share your story. The podcast wouldn’t be what it is without the incredible guests we have come and grace the M2M microphone. With even more amazing thought leaders on the horizon and a special celebration coming to DCAT Week, stay tuned for a jam-packed 2023...

Your host, Raman Sehgal, switches seats with journalist Dan Stanton as host for a celebration of 100 episodes of the podcast. They discuss;

• The Molecule to Market journey and how the podcast has evolved
• Raman’s experience with securing a private equity deal for sponsor of the podcast, ramarketing, the business he started in 2009 
• Valuable lessons learnt throughout the process including; how to get the best out of a guest, what didn’t work so well as the podcast evolved and breaking the podcast formula 
• What’s to come for the podcast and Raman in 2023 and beyond…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Raman’s review of life science in 2022

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with your host, Raman Sehgal, who reflects on the last 12 months in the life science industry.

He covers his 5 key trends from the year including:

• The biotech capital market slowdown and its impact on the outsourcing space
• Sustainability as the hot topic within the sector, from events to company practices
• Businesses operating in an increasingly digital way and what that means for the tech companies supporting them
• The cooling of mergers and acquisitions activity in the life sciences industry
• A reduction of discussion around Covid-19 as it moves into the sector’s rear view
  
  

Come back in 2023 for brand new episodes with great guests, including a special 100th episode celebration. Also, if you’re a previous guest, keep an eye out for an exclusive invitation in your inbox very soon…

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

A blast from the life science past

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with a look back to some of our early guests from the Molecule to Market archive.

Your host, Raman Sehgal, recaps his discussions on the pharmaceutical and biotechnology supply chain with:

• Stefano Console, founder and Senior Advisor at Oriento discussing: founding his business in Switzerland and the fractional management staffing structure that is helping Oriento succeed
• Claire Thompson, founder and CEO of Agility Life Sciences discussing: her career as a footballer and how it has helped her when successfully leading a team
• Jitesh Devendra, Managing Director at Solara Active Pharma Sciences discussing:  why it is crucial to invest time internally to be just as operationally focused as you are strategically focused
• Mary Christian, Senior Vice President, Regulatory at Lyndra Therapeutics discussing: her do’s and don’ts for building new business partnerships

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Tackling the 3 Big C’s: CDMO Career, Children & Cancer

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Sarah Stevens, SVP and Head of Early Development & Late Stage Commercial Operations at Quotient Sciences.
 
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sarah, covering:
 
Carving an incredible transatlantic CDMO career in traditionally non-female roles - balancing work, kids and breast cancer.
Words of wisdom for young women developing a career in the outsourcing space, including an appreciation of valuing the female perspective.
The concept of Translational Pharmaceutics® - delivering an agile and integrated offering for accelerating to first-in-human (FIH) clinical trials and optimizing dosage forms for proof-of-concept and beyond.
Potential impact of uncontrollable macro factors and current industry trends on demand for contract services and volunteer recruitment
 
Sarah is the Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing. Sarah oversees deployment of Quotient’s unique platform for integration, Translational Pharmaceutics, which eliminates white space between these traditionally silo’d drug development areas. Prior to this role, she was the Vice President of Drug Development Sciences, with responsibility for drug development consulting and creation of integrated programs across the organization.
 
Located in Boston, MA, Sarah’s experience spans a range of scientific and leadership roles within the drug product contract development and manufacturing space. Sarah received her PhD in Pharmaceutics from the University of Manchester and her MPharm, Pharmacy from Strathclyde University.
 
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
 
Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Mystic Miller’s review of ’22 and predictions for ’23

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with independent life sciences consultant Jim Miller. Your host, Raman Sehgal sits down with Jim covering:

• The three biggest macro factors impacting the CDMO space right now
• How CDMOs and CROs are starting to feel the pain of emerging biotech’s funding woes
• What we can learn from the 08-09 financial crash that can help CDMOs/CROs during rockier financial times
• The cooling of M&A and company valuations, and why financial stability may become a more important selection criteria
• Where Jim would place his attention and money if he was running a CDMO...

Jim Miller is a renowned expert in the space and a regular speaker at all the major trade conferences including CPhI WW. He made his name in the sector after founding and growing PharmSource with his wife Judy, an online database on bio/pharmaceutical intelligence, before selling the business to Global Data. Today, he’s an industry consultant and regularly writes for leading industry publications like DCAT and Pharmaceutical Technology.

Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.